NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.
A week-long power grab in the state Senate has left in limbo the future of the bill, which would award up to $3 million in tax credits to early-stage biotech companies that promise to relocate to or expand within the Big Apple.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
